TuHURA Biosciences, Inc. secures $12.5 million in a private equity financing to advance cancer immunotherapy treatments, with an additional $3.0 million from warrant exercises.

Jun 03, 2025•about 1 month ago

Amount Raised

$12.5 Million

TampaBiotechnology

Description

TuHURA Biosciences, Inc. has announced a definitive securities purchase agreement to issue $12.5 million in common stock through a private placement. The offering includes cash proceeds and warrant exercises totaling $3.0 million. The capital will help advance their pipeline of treatments to overcome resistance to cancer immunotherapy.

Company Information

Company

TuHURA Biosciences

Location

10500 University Center Drive

Tampa, Florida, United States

About

Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

TuHURA Biosciences, Inc. secures $12.5 million in a private equity financing to advance cancer immunotherapy treatments, with an additional $3.0 million from warrant exercises.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information